Yuan Meng, Liu Li, Wang Chenlin, Zhang Yan, Zhang Jiandong
School of Clinical Medicine, Weifang Medical University, Weifang 261053, China.
Medical Integration and Practice Center, Cheeloo College of Medicine, Shandong University, Jinan 250100, China.
Life (Basel). 2022 Sep 30;12(10):1532. doi: 10.3390/life12101532.
Liver cancer is the sixth most common cancer and the fourth most fatal cancer in the world. Immunotherapy has already achieved modest results in the treatment of liver cancer. Meanwhile, the novel and optimal combinatorial strategies need further research. The complement system, which consists of mediators, receptors, cofactors and regulators, acts as the connection between innate and adaptive immunity. Recent studies demonstrate that complement system can influence tumor progression by regulating the tumor microenvironment, tumor cells, and cancer stem cells in liver cancer. Our review concentrates on the potential role of the complement system in cancer treatment, which is a promising strategy for killing tumor cells by the activation of complement components. Conclusions: Our review demonstrates that complement components and regulators might function as biomarkers and therapeutic targets for liver cancer diagnosis and treatment.
肝癌是全球第六大常见癌症和第四大致命癌症。免疫疗法在肝癌治疗中已取得一定成效。与此同时,新型且最佳的联合治疗策略仍需进一步研究。补体系统由介质、受体、辅助因子和调节因子组成,是先天免疫和适应性免疫之间的桥梁。近期研究表明,补体系统可通过调节肝癌的肿瘤微环境、肿瘤细胞和癌症干细胞来影响肿瘤进展。我们的综述聚焦于补体系统在癌症治疗中的潜在作用,这是一种通过激活补体成分来杀死肿瘤细胞的有前景的策略。结论:我们的综述表明,补体成分和调节因子可能作为肝癌诊断和治疗的生物标志物及治疗靶点。